LinkedIn
WebsiteIntroduction
Applied DNA Sciences Inc (NASDAQ: APDN) is a biotechnology company headquartered in Stony Brook, New York. The firm develops and manufactures DNA-based technologies under its LineaDNA™ platform, which supports mRNA production, gene and cell therapies, diagnostics, and vaccines. It also offers supply-chain authentication solutions that protect products and brands from counterfeiting and diversion.
Corporate Structure
As of its 2024 Annual Report, Applied DNA Sciences employs between 51 and 200 people. The workforce includes roles in molecular biology, enzymatic DNA synthesis, manufacturing, quality assurance/control, regulatory compliance, information technology, business development, marketing, finance, and accounting. The company is publicly traded on the Nasdaq Stock Market and will change its ticker from APDN to BNBX effective October 7, 2025.
Biotechnology by Sangharsh Lohakare
Developments and News
- September 8, 2025: A Schedule 13G filing disclosed that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC each share voting and dispositive power over 143,336 shares, representing approximately 9.99% of the company’s common stock.
- September 23–26, 2025: The company’s LineaRx division participated in the 10th CAR-TCR Summit in Boston, discussing process scale-up and manufacturing timelines for cell therapies.
- September 23–25, 2025: LineaRx exhibited at the 4th mRNA Process Development & CMC Summit in Boston, showcasing PCR-based, cell-free manufacturing for synthetic DNA.
- October 1, 2025: Applied DNA filed an 8-K reporting material events, confirming corporate governance updates and other disclosures, though detailed financials were not included.
- October 7, 2025: The company will change its Nasdaq ticker to BNBX, indicating a new BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem, including integration of decentralized finance (DeFi) protocols.
- October 6, 2025: Shares closed at $5.34, reflecting a 25.06% increase on a volume of 1,268,798 shares.
Financial and Strategic Aspects
Applied DNA Sciences has not publicly released complete financial statements in its 8-K filings of September 29 and October 1, 2025. Full assessments of revenue growth, profitability, cash flow, and risk factors will require review of the company’s Form 10-Q and Form 10-K. Strategic priorities include:
- Transitioning treasury holdings into BNB to enhance capital efficiency and liquidity.
- Expanding the LineaDNA™ business for mRNA vaccines, cell and gene therapies, and diagnostics.
- Leveraging supply-chain authentication solutions across various industries, including textiles, cannabis, personal care, and packaging.
The Schedule 13G disclosure indicates a concentration of ownership, with key investors holding just under 10% collectively. Organizational and financial updates are expected to clarify the impact of these strategic shifts on operational performance and shareholder interests.
Market Position and Industry Context
Applied DNA Sciences operates in the biotechnology research and security software sectors. Its primary segments—DNA-based supply-chain authentication and large-scale synthetic DNA production—focus on demands for anti-counterfeiting measures and advanced therapeutic modalities. Competitors in synthetic DNA include Twist Bioscience, Ginkgo Bioworks, and Integrated DNA Technologies. In authentication, competitors range from specialty security-printing firms to broader blockchain-based provenance solutions. Applied DNA’s PCR-based, cell-free manufacturing is conducted in a GMP-compliant, ISO 9001/13485 facility, positioning it to support both research-grade programs and clinical GMP workflows.
tl;dr
- On October 7, 2025, Applied DNA Sciences will switch its Nasdaq ticker from APDN to BNBX to implement a BNB-based treasury strategy integrating DeFi protocols.
- Share price rose 25.06% to $5.34 on October 6, 2025, with trading volume of 1.27 million shares.
- SEC filings on September 8, 29, and October 1, 2025, report beneficial ownership at 9.99% for key investors and disclose material corporate events without detailed financials.
- The company’s focus remains on scaling LineaDNA™ for mRNA and gene-cell therapies and on supply-chain authentication while leveraging digital-asset strategies for treasury management. Future performance will depend on adoption of its DNA technologies and outcomes of its blockchain initiatives.
